MOPP/ABV hybrid program

Combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease

Paul Klimo, J. M. Connors

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

Seventy patients with advanced Hodgkin's disease, 54 with new disease, and 16 in first relapse after initial radiotherapy, have been treated with a seven-drug, 8-month program: MOPP (nitrogen mustard, vincristine, procarbazine, prednisone)/ABV (Adriamycin [Adria Laboratories of Canada, Mississauga, Ontario], bleomycin, vinblastine) hybrid. A single involved field of radiotherapy was given to selected partial responders after 6 months of chemotherapy. Forty-six of the 52 (88%) evaluable new-disease patients and 14 of the 16 (87%) evaluable patients with relapsing disease reached a complete response. The actuarial overall survival at 49 months for the patients with new disease was 90% (median follow-up from diagnosis was 27 months). For the patients with relapsing disease, the actuarial survival at 54 months was 79% (median follow-up from diagnosis was 27 months). The actuarial relapse-free survival at 41 months for complete responders was 93% for patients with new disease (median follow-up after treatment was 20 months) and 80% for those with relapsing disease (median follow-up after treatment was 27 months). Toxicity was moderate, with two treatment-related deaths and eight episodes of serious infection. These results compare favorably with the best results reported in the literature. Furthermore, they were achieved with a moderate level of toxicity, high drug delivery rates, and a relatively short duration of treatment. The efficacy and toxicity data of the MOPP/ABV hybrid program will now be evaluated in a prospectively randomized multicenter study.

Original languageEnglish (US)
Pages (from-to)1174-1182
Number of pages9
JournalJournal of Clinical Oncology
Volume3
Issue number9
DOIs
StatePublished - Jan 1 1985
Externally publishedYes

Fingerprint

Combination Drug Therapy
Hodgkin Disease
Pharmaceutical Preparations
Survival
Radiotherapy
Procarbazine
Recurrence
Mechlorethamine
Vinblastine
Bleomycin
Vincristine
Ontario
Therapeutics
Prednisone
Drug-Related Side Effects and Adverse Reactions
Doxorubicin
Multicenter Studies
Canada
Drug Therapy
Infection

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

MOPP/ABV hybrid program : Combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. / Klimo, Paul; Connors, J. M.

In: Journal of Clinical Oncology, Vol. 3, No. 9, 01.01.1985, p. 1174-1182.

Research output: Contribution to journalArticle

@article{79784870d0c1455697f9de2a84187603,
title = "MOPP/ABV hybrid program: Combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease",
abstract = "Seventy patients with advanced Hodgkin's disease, 54 with new disease, and 16 in first relapse after initial radiotherapy, have been treated with a seven-drug, 8-month program: MOPP (nitrogen mustard, vincristine, procarbazine, prednisone)/ABV (Adriamycin [Adria Laboratories of Canada, Mississauga, Ontario], bleomycin, vinblastine) hybrid. A single involved field of radiotherapy was given to selected partial responders after 6 months of chemotherapy. Forty-six of the 52 (88{\%}) evaluable new-disease patients and 14 of the 16 (87{\%}) evaluable patients with relapsing disease reached a complete response. The actuarial overall survival at 49 months for the patients with new disease was 90{\%} (median follow-up from diagnosis was 27 months). For the patients with relapsing disease, the actuarial survival at 54 months was 79{\%} (median follow-up from diagnosis was 27 months). The actuarial relapse-free survival at 41 months for complete responders was 93{\%} for patients with new disease (median follow-up after treatment was 20 months) and 80{\%} for those with relapsing disease (median follow-up after treatment was 27 months). Toxicity was moderate, with two treatment-related deaths and eight episodes of serious infection. These results compare favorably with the best results reported in the literature. Furthermore, they were achieved with a moderate level of toxicity, high drug delivery rates, and a relatively short duration of treatment. The efficacy and toxicity data of the MOPP/ABV hybrid program will now be evaluated in a prospectively randomized multicenter study.",
author = "Paul Klimo and Connors, {J. M.}",
year = "1985",
month = "1",
day = "1",
doi = "10.1200/JCO.1985.3.9.1174",
language = "English (US)",
volume = "3",
pages = "1174--1182",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - MOPP/ABV hybrid program

T2 - Combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease

AU - Klimo, Paul

AU - Connors, J. M.

PY - 1985/1/1

Y1 - 1985/1/1

N2 - Seventy patients with advanced Hodgkin's disease, 54 with new disease, and 16 in first relapse after initial radiotherapy, have been treated with a seven-drug, 8-month program: MOPP (nitrogen mustard, vincristine, procarbazine, prednisone)/ABV (Adriamycin [Adria Laboratories of Canada, Mississauga, Ontario], bleomycin, vinblastine) hybrid. A single involved field of radiotherapy was given to selected partial responders after 6 months of chemotherapy. Forty-six of the 52 (88%) evaluable new-disease patients and 14 of the 16 (87%) evaluable patients with relapsing disease reached a complete response. The actuarial overall survival at 49 months for the patients with new disease was 90% (median follow-up from diagnosis was 27 months). For the patients with relapsing disease, the actuarial survival at 54 months was 79% (median follow-up from diagnosis was 27 months). The actuarial relapse-free survival at 41 months for complete responders was 93% for patients with new disease (median follow-up after treatment was 20 months) and 80% for those with relapsing disease (median follow-up after treatment was 27 months). Toxicity was moderate, with two treatment-related deaths and eight episodes of serious infection. These results compare favorably with the best results reported in the literature. Furthermore, they were achieved with a moderate level of toxicity, high drug delivery rates, and a relatively short duration of treatment. The efficacy and toxicity data of the MOPP/ABV hybrid program will now be evaluated in a prospectively randomized multicenter study.

AB - Seventy patients with advanced Hodgkin's disease, 54 with new disease, and 16 in first relapse after initial radiotherapy, have been treated with a seven-drug, 8-month program: MOPP (nitrogen mustard, vincristine, procarbazine, prednisone)/ABV (Adriamycin [Adria Laboratories of Canada, Mississauga, Ontario], bleomycin, vinblastine) hybrid. A single involved field of radiotherapy was given to selected partial responders after 6 months of chemotherapy. Forty-six of the 52 (88%) evaluable new-disease patients and 14 of the 16 (87%) evaluable patients with relapsing disease reached a complete response. The actuarial overall survival at 49 months for the patients with new disease was 90% (median follow-up from diagnosis was 27 months). For the patients with relapsing disease, the actuarial survival at 54 months was 79% (median follow-up from diagnosis was 27 months). The actuarial relapse-free survival at 41 months for complete responders was 93% for patients with new disease (median follow-up after treatment was 20 months) and 80% for those with relapsing disease (median follow-up after treatment was 27 months). Toxicity was moderate, with two treatment-related deaths and eight episodes of serious infection. These results compare favorably with the best results reported in the literature. Furthermore, they were achieved with a moderate level of toxicity, high drug delivery rates, and a relatively short duration of treatment. The efficacy and toxicity data of the MOPP/ABV hybrid program will now be evaluated in a prospectively randomized multicenter study.

UR - http://www.scopus.com/inward/record.url?scp=0021930865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021930865&partnerID=8YFLogxK

U2 - 10.1200/JCO.1985.3.9.1174

DO - 10.1200/JCO.1985.3.9.1174

M3 - Article

VL - 3

SP - 1174

EP - 1182

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -